- Home
- LSF vs ASRT Comparison
LSF vs ASRT Comparison
Compare LSF & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- ASRT
- Stock Information
- Founded
- LSF 2015
- ASRT 1995
- Country
- LSF United States
- ASRT United States
- Employees
- LSF N/A
- ASRT N/A
- Industry
- LSF Packaged Foods
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- LSF Consumer Staples
- ASRT Health Care
- Exchange
- LSF Nasdaq
- ASRT Nasdaq
- Market Cap
- LSF 90.1M
- ASRT 105.8M
- IPO Year
- LSF 2020
- ASRT 1997
- Fundamental
- Price
- LSF $8.56
- ASRT $0.81
- Analyst Decision
- LSF Strong Buy
- ASRT Strong Buy
- Analyst Count
- LSF 2
- ASRT 4
- Target Price
- LSF $7.75
- ASRT $3.19
- AVG Volume (30 Days)
- LSF 163.5K
- ASRT 862.2K
- Earning Date
- LSF 11-06-2024
- ASRT 11-11-2024
- Dividend Yield
- LSF N/A
- ASRT N/A
- EPS Growth
- LSF N/A
- ASRT N/A
- EPS
- LSF N/A
- ASRT N/A
- Revenue
- LSF $40,896,326.00
- ASRT $125,763,000.00
- Revenue This Year
- LSF $21.72
- ASRT N/A
- Revenue Next Year
- LSF $10.16
- ASRT $4.68
- P/E Ratio
- LSF N/A
- ASRT N/A
- Revenue Growth
- LSF 20.33
- ASRT N/A
- 52 Week Low
- LSF $0.71
- ASRT $0.73
- 52 Week High
- LSF $10.35
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- LSF 61.10
- ASRT 30.77
- Support Level
- LSF $8.16
- ASRT $0.82
- Resistance Level
- LSF $10.35
- ASRT $1.07
- Average True Range (ATR)
- LSF 0.91
- ASRT 0.07
- MACD
- LSF 0.03
- ASRT -0.02
- Stochastic Oscillator
- LSF 48.57
- ASRT 8.29
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.